1. Market Research
  2. > Cardiovascular Risk Factors – Pipeline Review, H1 2013

Cardiovascular Risk Factors – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 465 pages

Cardiovascular Risk Factors – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Cardiovascular Risk Factors - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Risk Factors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Risk Factors. Cardiovascular Risk Factors - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiovascular Risk Factors.
- A review of the Cardiovascular Risk Factors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiovascular Risk Factors pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiovascular Risk Factors.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiovascular Risk Factors pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cardiovascular Risk Factors - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
Introduction 7
Cardiovascular Risk Factors Overview 8
Therapeutics Development 9
Cardiovascular Risk Factors Therapeutics under Development by Companies 11
Cardiovascular Risk Factors Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
Cardiovascular Risk Factors Therapeutics - Products under Development by Companies 25
Cardiovascular Risk Factors Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Cardiovascular Risk Factors Therapeutics Development 36
Cardiovascular Risk Factors - Therapeutics Assessment 126
Drug Profiles 134
Cardiovascular Risk Factors Therapeutics - Drug Profile Updates 355
Cardiovascular Risk Factors Therapeutics - Discontinued Products 420
Cardiovascular Risk Factors Therapeutics - Dormant Products 423
Cardiovascular Risk Factors - Product Development Milestones 437
Appendix 446



List of Tables

Number of Products Under Development for Cardiovascular Risk Factors, H1 2013 27
Products under Development for Cardiovascular Risk Factors - Comparative Analysis, H1 2013 28
Number of Products under Development by Companies, H1 2013 30
Number of Products under Investigation by Universities/Institutes, H1 2013 38
Comparative Analysis by Late Stage Development, H1 2013 39
Comparative Analysis by Mid Clinical Stage Development, H1 2013 40
Comparative Analysis by Early Clinical Stage Development, H1 2013 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 42
Products under Development by Companies, H1 2013 43
Products under Investigation by Universities/Institutes, H1 2013 53
Bristol-Myers Squibb Company, H1 2013 54
F. Hoffmann-La Roche Ltd., H1 2013 55
Shionogi and Co., Ltd., H1 2013 56
Sanofi-Aventis, H1 2013 57
AstraZeneca PLC, H1 2013 58
Eli Lilly and Company, H1 2013 59
GlaxoSmithKline plc, H1 2013 60
Isis Pharmaceuticals, Inc., H1 2013 61
Daiichi Sankyo Company, Ltd, H1 2013 62
Merck and Co., Inc., H1 2013 63
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 64
Takeda Pharmaceutical Company Limited, H1 2013 65
BioLineRx, Ltd., H1 2013 66
Novartis AG, H1 2013 67
Samyang Corporation, H1 2013 68
Actelion Ltd, H1 2013 69
Astellas Pharma Inc., H1 2013 70
Axcan Pharma Inc., H1 2013 71
Biocon Limited, H1 2013 72
Chong Kun Dang Pharmaceutical, H1 2013 73
Daewoong Pharmaceutical Co., Ltd., H1 2013 74
Dong-A Pharmaceutical Co., Ltd., H1 2013 75
Forest Laboratories, Inc., H1 2013 76
Les Laboratoires Servier, H1 2013 77
Mitsubishi Tanabe Pharma Corporation, H1 2013 78
Nippon Shinyaku Co., Ltd., H1 2013 79
Recordati S.p.A., H1 2013 80
Zydus Cadila Healthcare Limited, H1 2013 81
Bayer AG, H1 2013 83
Amarin Corporation plc, H1 2013 84
IntelGenx Technologies Corp., H1 2013 85
Medivir AB, H1 2013 86
Mesoblast Ltd, H1 2013 87
Compugen Ltd., H1 2013 88
Palatin Technologies, Inc., H1 2013 89
BTG International Ltd, H1 2013 90
Cytokinetics, Inc, H1 2013 91
Yuhan Corporation, H1 2013 92
Bio3 Research S.r.l, H1 2013 93
XOMA Ltd., H1 2013 94
Torrent Pharmaceuticals Limited, H1 2013 95
Choongwae Pharma Corp, H1 2013 96
Hanall Pharmaceutical Co., Ltd., H1 2013 97
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 98
LG Life Sciences, Ltd, H1 2013 99
AnGes MG, Inc., H1 2013 100
Panacea Biotec Limited, H1 2013 101
CytoTools AG, H1 2013 102
DiaMedica Inc., H1 2013 103
Proteo, Inc., H1 2013 104
Angelini Group, H1 2013 105
AFFiRiS AG, H1 2013 106
Viron Therapeutics, Inc., H1 2013 107
Respiratorius AB, H1 2013 108
Spherix Incorporated, H1 2013 109
Ache Laboratorios Farmaceuticos S/A, H1 2013 110
Anacor Pharmaceuticals, Inc., H1 2013 111
IMMD Inc., H1 2013 112
AngioDesign, H1 2013 113
ProtAffin Biotechnologie AG, H1 2013 114
Amalyte Pharmaceuticals, LLC, H1 2013 115
Catabasis Pharmaceuticals, Inc., H1 2013 116
Mondobiotech Holding AG, H1 2013 117
PhaseBio Pharmaceuticals, Inc., H1 2013 118
INNOPHARMAX, INC., H1 2013 119
QUANTUM GENOMICS Corp., H1 2013 120
AIM Therapeutics Inc., H1 2013 121
Cardax Pharmaceuticals, Inc., H1 2013 122
Intercept Pharmaceuticals, Inc., H1 2013 123
Cellceutix Corporation, H1 2013 124
Essentialis, Inc., H1 2013 125
Diakron Pharmaceuticals, Inc., H1 2013 126
Athera Biotechnologies AB, H1 2013 127
Biolink Group AS, H1 2013 128
Proreo Pharma AG, H1 2013 130
Bial - Portela and Ca, S.A., H1 2013 131
BioAxone Therapeutic Inc., H1 2013 132
Lee's Pharmaceutical Holdings Limited, H1 2013 133
miRagen Therapeutics, Inc., H1 2013 134
CSPC NBP Pharmaceutical Co.,ltd, H1 2013 135
Sihuan Pharmaceutical Holdings Group Ltd., H1 2013 136
MicroDose Therapeutx, Inc., H1 2013 137
Vicore Pharma AB, H1 2013 138
Laila Pharmaceuticals Pvt. Ltd., H1 2013 139
XBiotech USA, Inc., H1 2013 140
Kotobuki Pharmaceutical Co., Ltd., H1 2013 141
FORMAC Pharmaceuticals N.V., H1 2013 142
Serodus AS, H1 2013 143
Assessment by Monotherapy Products, H1 2013 144
Assessment by Combination Products, H1 2013 145
Assessment by Stage and Route of Administration, H1 2013 148
Assessment by Stage and Molecule Type, H1 2013 151
Cardiovascular Risk Factors Therapeutics - Drug Profile Updates 373
Cardiovascular Risk Factors Therapeutics - Discontinued Products 438
Cardiovascular Risk Factors Therapeutics - Dormant Products 441



List of Figures

Number of Products under Development for Cardiovascular Risk Factors, H1 2013 27
Products under Development for Cardiovascular Risk Factors - Comparative Analysis, H1 2013 28
Products under Development by Companies, H1 2013 29
Products under Investigation by Universities/Institutes, H1 2013 37
Late Stage Products, H1 2013 39
Mid Clinical Stage Products, H1 2013 40
Early Clinical Stage Products, H1 2013 41
Discovery and Pre-Clinical Stage Products, H1 2013 42
Assessment by Monotherapy Products, H1 2013 144
Assessment by Combination Products, H1 2013 145
Assessment by Route of Administration, H1 2013 146
Assessment by Stage and Route of Administration, H1 2013 147
Assessment by Molecule Type, H1 2013 149
Assessment by Stage and Molecule Type, H1 2013 150

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.